Category: Startup News

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-highlights-progress-pain-management-and-cinv SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its

Clinithink secures growth-equity investment to fuel growth

From Startup Clinithink Link to Full Article: https://clinithink.com/clinithink-secures-growth-equity/ Leading healthcare technology investors partner with Clinithink to unlock the potential of unstructured data to inform treatment decisions, identify candidates for clinical trials, and ensure appropriate reimbursement   Clinithink, which offers healthcare and life sciences organizations powerful clinical data insights through its

Sigilon Therapeutics and MIT Announce Research Collaboration to Advance Programmable Living Therapeutics for Serious Chronic Diseases

From Startup Sigilon Therapeutics Link to Full Article: http://sigilon.com/2019/01/07/sigilon-therapeutics-and-mit-announce-research-collaboration-to-advance-programmable-living-therapeutics-for-serious-chronic-diseases/ CAMBRIDGE, Mass. — January 7, 2019 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration. The collaboration leverages cutting-edge synthetic biology approaches developed by professor Ron Weiss

https://decibeltx.com/wp-content/uploads/2019/01/Decibel_Cocoon-Press-Release-Jan-7-2019-1.pdf

From Startup Decibal Therapeutics Decibel Therapeutics has established the world’s first comprehensive drug discovery, development, and translational research platform to discover and develop the first therapeutics to protect, repair, and restore hearing. To serve the over half billion people globally living with hearing loss and related disorders, Decibel is committed

Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome

From Startup Urovant Link to Full Article: https://urovant.com/2019/01/04/urovant-sciences-initiates-patient-enrollment-in-phase-2a-clinical-trial-for-vibegron-in-patients-with-abdominal-pain-due-to-irritable-bowel-syndrome/ BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Jan. 3, 2019– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with

Genevant President & CEO Dr. Bo Rode Hansen to Present at Biotech Showcase 2019

From Startup Genevant Link to Full Article: https://genevant.com/genevant-president-ceo-dr-bo-rode-hansen-to-present-at-biotech-showcase-2019/ BOSTON, MASSACHUSETTS; BURNABY, CANADA; and BASEL, SWITZERLAND – January 3, 2019 – Genevant Sciences, a leading biopharmaceutical company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics across multiple modalities, announced today that its President & CEO

BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2381958 NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview

90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/90-patients-remain-opioid-free-when-htx-011-given-over-counter SAN DIEGO, Jan. 3, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a

Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference

From Startup Aduro Biotech Link to Full Article: BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco,